Obesity Prevention in Children and Young People Treated for Acute Lymphoblastic Leukaemia with ALLTogether

NCT ID: NCT06846294

Last Updated: 2025-02-26

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 90 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-04-01
• Study Completion Date: 2029-12-31

Brief Summary

Background Leukaemia is the most common cancer in children with 800 diagnoses per year in England. To survive, children need strong treatments like chemotherapy and steroids given usually through clinical trials. The current trial used by the NHS is called ALLTogether. Fifty percent of children become obese during treatment due to increased hunger, cravings for junk foods and lack of physical activity. Obesity raises the chance of cancer relapse by 31%, makes treatment side-effects worse and makes it harder to kill off leukaemia cells, which affects how well children do during treatment, as indicated by minimal residual disease, a key predictor of prognosis.

Aims and Objectives This study (called BREVARY) aims to see if we can successfully provide personalised diet and physical activity with behaviour support for children and young people with leukaemia who are being treated with the ALLTogether trial. It will help us figure out if we can perform a bigger study, if this programme could reduce obesity and side-effects and improve survival and wellbeing.

How it will be done We plan to randomly assign participants to one of three groups; one group will get both a diet and physical activity plan, another will get only a diet plan, and the last group will receive standard care. This will take place in Hospital Infantil Universitario Nino Jesus, Madrid and Bristol Royal Hospital for Children and Southwest England NHS-sites. The diet and exercise plans will be created in partnership with the children and their families and delivered online or during regular hospital visits. The diet will follow healthy eating guidelines, consider personal food preferences (including cultural and religious needs), treatment side-effects and personal finances. Assessments of fitness and strength will be taken to plan personalised activities. During the study, the following data will also be collected: weight, height, body fat, diet, biomarkers, microbiome, muscle strength and wellbeing at three different times. "One to one" interviews will be conducted at the end to obtain feedback on their experiences with BREVARY.

This study aims to find out if children and their families/carers are willing to participate in BREVARY, if enough people sign up and stay until the end and if our interventions and health measurements are appropriate.

Potential Impact The results will help determine if a larger study can be performed, if changes are needed and what the cost will be. The study will be disseminated through networks, targeting underserved communities, healthcare professionals and affected families using accessible platforms to spread the word.

Detailed Description

The international randomised controlled trial registry shows that no lifestyle intervention (diet, physical activity with integrated counselling) has been performed in the UK. The IDEAL trial performed in the USA demonstrated that diet with energy intake restriction and physical activity was feasible and significantly improved Minimal Residual Disease (MRD) in children diagnosed with Acute lymphoblastic leukaemia (CYP_ALL) and treated with National Cancer Institute/Rome high-risk B-ALL protocol during induction. ALLTogether is similar and will for the first time provide an excellent platform to prevent obesity in CYP_ALL.

Obesity associated relapse is attributed to adipocyte-mediated chemo-resistance, which occurs in CYP_ALL with higher fat mass and leads to more persistent MRD. MRD is a marker of leukaemic cells and the strongest predictor of prognosis including both remission and relapse. Therefore, obesity is identified as a prognostic factor for relapse (measured by MRD) and it is associated with increased morbidity and mortality, and poorer wellbeing.

Only two dietary feasibility interventions have investigated CYP_ALL differing in the type (diet alone vs. diet and physical activity) and the length of intervention (1 - 6 months). Both showed improvements in diet quality, high participation (>70%) and 56 - 82% adherence. Indeed, the IDEAL trial also showed improvements in MRD and body composition, making it suitable to base BREVARY's design. Consensus exists regarding using patient-centre interventions in clinical settings; like the Individualised Macronutrient Meal-Equivalent Menu (Menus). This approach reduces food associated stress, anxiety and financial costs, while empowering patients and their families/carers, thus improving adherence. It has been shown to be successful in adults with breast cancer and provides a validated approach to CYP_ALL.

A systematic review showed that individualised physical activity combining fitness and strength mitigated complications in CYP_ALL. However, it was difficult to draw firm conclusions because evidence were limited by sample sizes, adherence was seldom reported and study designs were heterogenous differing in length (1 - 30 months), exercise type and intensity and assessed outcomes (e.g. cardiorespiratory fitness, strength and wellbeing). Six trials are underway including all cancers with interventions being either individualised ("as able" and play-based exercise for children aged <5 years) or employing generic exercise prescriptions with intensity "as able". They are investigating fitness, strength and wellbeing; however, none have incorporated dietary assessment or intervention.

4. Research proposal

Aim

Investigate the feasibility of conducting a randomised controlled trial (RCT) to prevent obesity in CYP_ALL and treated with ALLTogether.

The hypothesis is that BREVARY will reduce obesity rates, improve clinical outcomes by reducing side-effects and relapse and improving CYP_ALL and their families/carers' quality of life. BREVARY will establish if a multi-site RCT is feasible and acceptable to families and clinical teams, examine recruitment and data collection strategies, and assess candidate outcomes.

BREVARY comprises three workstreams (WS):

WS1: Implementing a RCT of BREVARY for 3 months involving newly diagnosed CYP_ALL treated with ALLTogether in SW England NHS-sites and Hospital Infantil Universitario Nino Jesus Madrid WS2: Process evaluation of BREVARY RCT examining feasibility and maintenance of intervention (3 months intervention, maintenance at 6 months) WS3: Assessment of feasibility of progression to a definitive trial, including setting trial parameters

Objectives

• Assess recruitment, including acceptability of randomisation to stakeholders, across ethnically, geographically and socially diverse communities (WS1)
• Assess interventions acceptability and retention (WS1/WS2)
• Assess feasibility and appropriateness of quantitative and qualitative outcomes (WS1)
• Assess RCT resource implications of interventions and potential service use savings (WS1/WS3)
• Assess fidelity and adherence to protocol within interventions and control groups (WS1/WS2)
• Assess feasibility of progression to a definitive trial, set out main parameters and estimate both sample size and cost of a RCT (WS3)

Project plan

WS1: Implementing BREVARY

Study design BREVARY is phase 2 of Medical Research Council framework for complex interventions. Development and identification of the complex intervention (phase 1) was performed based on the IDEAL pilot-trial. BREVARY was designed in consultation with NIHR Nutrition and Cancer and PPI, reviewed by NIHR RSS and is supported by ALLTogether sponsors (UK and Spain).

Feasibility three-arm non-blinded parallel RCT with integrated quantitative and qualitative measures. Quantitative measures will be performed at baseline, end of induction (4 - 6 weeks) and during consolidation treatment (3 months weeks) and a follow up at 6 months. Qualitative measures will be performed at the end of BREVARY in a sample subgroup. The three-arms include combined diet and physical activity, diet only and standard care.

Recruitment Recruitment will be conducted by researchers. Inclusion criteria

• CYP aged between 2 - 21 years.
• Newly diagnosed and relapse CYP_ALL treated in University Hospital Bristol and Weston NHS Foundation Trust and Hospital Infantil Universitario Nino Jesus, Madrid
• Within two weeks of being recruited to ALLTogether.
• Treated with curative intent. Exclusion criteria
• CYP not partaking in ALLTogether.
• CYP treated with palliative intent.
• Those excluded by NHS-staff for clinical reasons. BREVARY aims to recruit 10 - 15 in each arm and each international centre (n= 60 - 90 in SW England and Madrid; 50% recruitment rate, which is below previous studies and the IDEAL trial to test feasibility and to calculate the variability of reliable estimates of continuous variables.

Eligible participants will be randomised using computer-generated restricted (nutritional status, age and sex) randomisation procedure in 1:1:1 ratio.

BREVARY Intervention (table 1)

Twenty % energy deficit and equicaloric intervention will be applied to those classified as overweight/obese and healthy weight respectively by diet (- 20%).

Researchers will deliver weekly one-to-one supervised sessions during induction and fortnightly during consolidation (total 8 sessions) online/home or at routine appointments. Physical activity intervention will include two additional sessions supervised non-consecutive sessions as tolerated. Both designed following PPI preferences.

Dietary intervention Menus based on Eatwell guide in the UK and Food and Agriculture Organisation in Spain will be used. Menus consists of prescribing 7 interchangeable meal options matched in energy and macronutrients requirements to reduce participants meal planning burden. It accounts for side-effects, psycho-social factors and religious, cultural, personal (and PPI) preferences. Nutritics® will be used to create Menus and estimate nutrients.

CYP_ALL referred to Dietetics will receive the intervention post-Dietetic discharged to avoid interference with nutritional support.

Physical activity intervention Individualised plans will be prescribed based on fitness and clinical condition. The programme will start at enrolment unless contraindicated. Sessions will include a combination of aerobic, balance and resistance exercise based on individual fitness and strength, age and clinical history as well as individual preferences and available equipment.

Standard care CYP_ALL will receive usual care (described in "The problem"). Counselling sessions for CYP_ALL and families/carers (all groups) Counselling sessions were requested by PPI and are recommended for motivation and adherence in long-term clinical interventions.

Two online/home (or at routine appointments) one-to-one sessions will be delivered. Sessions will be designed by all co-applicants, reviewed by our clinical psychologist and delivered by the researchers with PPI CoA support and focusing on:

(i) Diet and physical activity benefits (ii) Behaviour and autonomy (iii) Difficulties encountered and how to address them (iv) Motivation Data collection (all groups)

• Eligible CYP_ALL
• Eligible CYP_ALL approached to participate
• Families declining intervention before randomisation, after randomisation and after the first set of measurements (before follow-ups)
• Families allocated to interventions dropping out between second and final follow-up
• Families allocated to standard care dropping out between second and final follow-up

Health Electronic Records (HER) will be accessed to collect demographics (CYP_ALL sex, ethnicity and age), socio-economics (parents' relationship status, siblings, employment status, education level, income and housing status), clinical (diagnosis, treatments, side-effects, hospital admissions), routine biomarkers (MRD, immunoglobulins, full blood count, total cholesterol, high density lipoprotein and low density lipoprotein and glucose) and other biomarkers (leptin and adiponectin) and stool samples (microbiome). Participants' postcodes will be linked to the Indices of Multiple Deprivation.

Based on the IDEAL trial, feasibility and acceptability and PPI feedback, the following outcome measures will be taken at baseline, 4 - 6 weeks, 3 months and a follow up at 6 months (to assess intervention sustainability - no intervention from 3 - 6 months).

• Weight, height and body composition (Multi-frequency Bio-electrical Impedance)
• Dietary intake using a multiple-pass 24 hour recall
• Seven days physical activity levels at each follow up using GENEActiv accelerometers, strength by hand-held hydraulic dynamometer and fitness by 15-foot walk (excluding children aged <5y).
• CYP_ALL and their families/carers' QoL will be assessed at baseline and at completion using two validated questionnaires PedQL-Cancer and Parents PedQL-Cancer.

We will determine primary and secondary candidate outcome measures for future trial based on performance of selected measures.

Candidate primary outcome measures for definitive trial

• Body mass index Z-score (≤ 19 years)
• Muscle and fat mass percentage
• MRD
• Quality of Life: PedQL-Cancer and Parents PedQL-Cancer Candidate secondary outcome measures for definitive trial
• Biomarkers and Microbiome
• Food group indicators and nutrient intake
• Physical activity levels
• Hand strength (percentiles 5 ≤ 18 years)
• CPET - Fitness excluding children aged < 5 years
• Clinical outcomes, number and type of treatment side-effects and intervention side-effects
• Hospital admissions
• Changes in treatment regime (ALLTogether)
• Microbiome: composition and diversity of microbiome

Analysis CONSORT flow diagram will be used to report participant flow and descriptive statistics for demographics, clinical and socio-economic data with overall data and stratified by arm. Appropriate distribution or frequencies will be used (count/percentages, mean/SD and median/IQR). IBM_SPSS statistics® will be used for analysis and a Statistical Analysis Plan will be signed-off prior to any analysis taking place.

WS2: Process evaluation The process evaluation assesses how implementation of BREVARY is achieved, influenced by contextual factors including randomisation and trial design, and quality of implementation and acceptability. The following stakeholders will be included: Parents/carers whose CYP_ALL partake in BREVARY, CYP_ALL able to understand the questions and communicate an answer and researchers plus NHS-staff directly involved in implementing BREVARY. RE-AIM (http://www.re-aim.org/) based on reach, effectiveness, adoption, implementation and maintenance will be used.

Semi-structured one-to-one online (or at routine appointment) interviews will be conducted to a subgroup (n = 15) with equal representation from each arm to explore enjoyment:

• Best and worst things about partaking
• Overall satisfaction
• Likelihood to recommend BREVARY
• Reasons for dropping out Facilitator records will be completed by the researchers using structured case-records to collect RE-AIM

Analysis Quantitative survey data will be analysed using descriptive statistics. Free text responses will be analysed using thematic analysis and audio recordings will be transcribed, anonymised and data analysed using thematic analysis in Nvivo®.

Fidelity: Intervention delivery (usage statistics), receipt (usage statistics and interviews) and enactment (interviews, questionnaires and measurements) as well as repeated engagement (usage statistics and counselling sessions) will be conducted separately. Findings will be integrated following a triangulation protocol to assess whether data agree (convergence), complement one another (complementary), or contradict each other (dissonance).

WS3: Progression criteria and definitive RCT design

Results from WS1 and WS2 will be reviewed by all co-applicants. A trial will be regarded feasible if the following criteria are met:

Progression criteria and definitive RCT design

• Recruitment rate ≥ 50%
• ≥ 70% of recruited families complete the trial in one of the intervention groups
• ≥ 70% of families, researchers and clinical staff agree that the intervention is acceptable (RE-AIM)
• Recruited participants complete ≥ 60% of the supervised sessions (RE-AIM)
• ≥ 70% of families agree that the intervention is enjoyable

Health economics Within-trial economic and resource use analysis based on complex intervention protocols will be used. This reduces participants' burden and meets PPI feedback.

The within-trial analysis will investigate the cost-effectiveness of each arm. The primary within-trial analysis used in the full trial will be a cost-utility-analysis (CUA), which estimates the incremental cost per quality adjusted life (QALY) of each arm. QALY will be generated via measurement of utility values using PedsQL-cancer and Parents PedQL-Cancer instrument mapped to the EQ-5D.

The resource use analysis will be estimated using HER. Data (e.g. admissions, medication) will be collected by researchers. A cost-consequences framework will be used to describe resources used and benefits gained from the intervention without developing a full cost-effectiveness estimate.

Conditions

Diet Intervention; Physical Activity Intervention; Standard Care Control

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: SUPPORTIVE_CARE
• Blinding Strategy: NONE

Study Groups

Diet

Individualised Dietary Intervention

Group Type: EXPERIMENTAL

Diet

Intervention Type: BEHAVIORAL

Individualised dietary intervention

Diet and Physical Activity

Individualised Dietary and Physical Activity Intervention

Group Type: EXPERIMENTAL

Diet and physical activity

Intervention Type: BEHAVIORAL

Obesity prevention: Diet, Diet and physical activity and standard care

Standard Care

No intervention - this is standard care

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Diet

Individualised dietary intervention

Intervention Type: BEHAVIORAL

Diet and physical activity

Obesity prevention: Diet, Diet and physical activity and standard care

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

• CYP aged between 5 - 21 years.
• Newly diagnosed or relapsed CYP_ALL treated in University Hospital Bristol and Weston NHS Foundation Trust and Hospital Infantil Universitario Nino Jesus, Madrid
• Within two weeks of being recruited to ALLTogether.
• Treated with curative intent.

Exclusion Criteria

• CYP not partaking in ALLTogether.
• CYP treated with palliative intent.
• Those excluded by healthcare professionals or clinical reasons

• Minimum Eligible Age: 5 Years
• Maximum Eligible Age: 21 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Exeter

OTHER

Sponsor Role: lead

Responsible Party

Raquel Revuelta Iniesta

Senior Lecturer in Nutrition

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Raquel Revuelta Iniesta, PhD

Role: STUDY_CHAIR

University of Exeter

Carmen Fiuza Luces, PhD

Role: STUDY_CHAIR

Hospital 12 de Octubre Research Institute

Raquel Revuelta Iniesta, PhD

Role: STUDY_DIRECTOR

University of Exeter

Locations

Hospital Infantil Universitario Nino Jesus

Madrid, Madrid, Spain

University Hospitals Bristol & Weston NHS Trust

Bristol, Somerset, United Kingdom

Countries

Spain; United Kingdom

Central Contacts

Raquel Revuelta Iniesta, PhD

Role: CONTACT

r.revuelta-iniesta@exeter.ac.uk

0044 07715303535

Raquel Fiuza Luces, PhD

Role: CONTACT

r.revuelta-iniesta@exeter.ac.uk

0034 658961509

Facility Contacts

Carmen Fiuza Luces, PhD

Role: primary

cfiuza.imas12@h12o.es

0034 658961509

Alejandro Lucia Mulas, PhD

Role: backup

alejandro.lucia@universidadeuropea.es

Carmen Fiuza Luces, PhD

Role: backup

Laura Sealy, MSc

Role: primary

laura.sealy@uhbw.nhs.uk

0117 342 0811 ext. ask for Laura

Helen Morris, BSc

Role: backup

helen.morris@uhbw.nhs.uk

Raquel Revuelta Iniesta, PhD

Role: backup

References

Khan KA, Petrou S, Rivero-Arias O, Walters SJ, Boyle SE. Mapping EQ-5D utility scores from the PedsQL generic core scales. Pharmacoeconomics. 2014 Jul;32(7):693-706. doi: 10.1007/s40273-014-0153-y.

Reference Type: BACKGROUND

PMID: 24715604 (View on PubMed)

O'Cathain A, Murphy E, Nicholl J. Three techniques for integrating data in mixed methods studies. BMJ. 2010 Sep 17;341:c4587. doi: 10.1136/bmj.c4587. No abstract available.

Reference Type: BACKGROUND

PMID: 20851841 (View on PubMed)

Arnetz J, Sudan S, Goetz C, Arnetz B, Gowland L, Manji S, Ghosh S. Preliminary development of a questionnaire measuring patient views of participation in clinical trials. BMC Res Notes. 2019 Oct 21;12(1):667. doi: 10.1186/s13104-019-4724-z.

Reference Type: BACKGROUND

PMID: 31639069 (View on PubMed)

Deidda M, Boyd KA, Minnis H, Donaldson J, Brown K, Boyer NRS, McIntosh E; BeST study team. Protocol for the economic evaluation of a complex intervention to improve the mental health of maltreated infants and children in foster care in the UK (The BeST? services trial). BMJ Open. 2018 Mar 14;8(3):e020066. doi: 10.1136/bmjopen-2017-020066.

Reference Type: BACKGROUND

PMID: 29540420 (View on PubMed)

Braun V, Clarke V (2006) Using thematic analysis in psychology. Qual. Res.Psychol 3, 77-101

Reference Type: BACKGROUND

Fielding D, Duff A. Compliance with treatment protocols: interventions for children with chronic illness. Arch Dis Child. 1999 Feb;80(2):196-200. doi: 10.1136/adc.80.2.196. No abstract available.

Reference Type: BACKGROUND

PMID: 10325743 (View on PubMed)

Gibson AA, Sainsbury A. Strategies to Improve Adherence to Dietary Weight Loss Interventions in Research and Real-World Settings. Behav Sci (Basel). 2017 Jul 11;7(3):44. doi: 10.3390/bs7030044.

Reference Type: BACKGROUND

PMID: 28696389 (View on PubMed)

Varni JW, Katz ER, Seid M, Quiggins DJ, Friedman-Bender A, Castro CM. The Pediatric Cancer Quality of Life Inventory (PCQL). I. Instrument development, descriptive statistics, and cross-informant variance. J Behav Med. 1998 Apr;21(2):179-204. doi: 10.1023/a:1018779908502.

Reference Type: BACKGROUND

PMID: 9591169 (View on PubMed)

Varni JW, Burwinkle TM, Katz ER, Meeske K, Dickinson P. The PedsQL in pediatric cancer: reliability and validity of the Pediatric Quality of Life Inventory Generic Core Scales, Multidimensional Fatigue Scale, and Cancer Module. Cancer. 2002 Apr 1;94(7):2090-106. doi: 10.1002/cncr.10428.

Reference Type: BACKGROUND

PMID: 11932914 (View on PubMed)

Rehorst-Kleinlugtenbelt LB, et al. (2019) Physical activity level objectively measured by accelerometery in children undergoing cancer treatment at home and in a hospital setting: A pilot study. J. Pediatr. Hematol. Oncol. 4, 82-88

Reference Type: BACKGROUND

Russell DJ, Rosenbaum PL, Cadman DT, Gowland C, Hardy S, Jarvis S. The gross motor function measure: a means to evaluate the effects of physical therapy. Dev Med Child Neurol. 1989 Jun;31(3):341-52. doi: 10.1111/j.1469-8749.1989.tb04003.x.

Reference Type: BACKGROUND

PMID: 2753238 (View on PubMed)

Reilly JJ, Montgomery C, Jackson D, MacRitchie J, Armstrong J. Energy intake by multiple pass 24 h recall and total energy expenditure: a comparison in a representative sample of 3-4-year-olds. Br J Nutr. 2001 Nov;86(5):601-5. doi: 10.1079/bjn2001449.

Reference Type: BACKGROUND

PMID: 11737958 (View on PubMed)

Kang M, Ragan BG, Park JH. Issues in outcomes research: an overview of randomization techniques for clinical trials. J Athl Train. 2008 Apr-Jun;43(2):215-21. doi: 10.4085/1062-6050-43.2.215.

Reference Type: BACKGROUND

PMID: 18345348 (View on PubMed)

R. RDAHI (2015) Complex Interventions in Health: An Overview of Research Methods. 1st ed. Oxford: Routledge

Reference Type: BACKGROUND

Pasquet M (2022) Adapted Physical Activity for Children Treated With Cancer and Insulin Sensitivity (APACIS).

Reference Type: BACKGROUND

Mochel J (2021) LCI-PED-NOS-EXER-001: Exercise in Pediatric Oncology Patients.

Reference Type: BACKGROUND

Skivington K, Matthews L, Simpson SA, Craig P, Baird J, Blazeby JM, Boyd KA, Craig N, French DP, McIntosh E, Petticrew M, Rycroft-Malone J, White M, Moore L. A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance. BMJ. 2021 Sep 30;374:n2061. doi: 10.1136/bmj.n2061.

Reference Type: BACKGROUND

PMID: 34593508 (View on PubMed)

Culos-Reed NS (2021) IMPACT: Implementation of Physical Activity for Children.

Reference Type: BACKGROUND

Limon-Miro AT, Lopez-Teros V, Astiazaran-Garcia H. Dynamic Macronutrient Meal-Equivalent Menu Method: Towards Individual Nutrition Intervention Programs. Methods Protoc. 2019 Sep 5;2(3):78. doi: 10.3390/mps2030078.

Reference Type: BACKGROUND

PMID: 31491882 (View on PubMed)

López Teros V (2021) Nutritional Intervention in Acute Lymphoblastic Leukemia (ALL).

Reference Type: BACKGROUND

Friend AJ, Feltbower RG, Hughes EJ, Dye KP, Glaser AW. Mental health of long-term survivors of childhood and young adult cancer: A systematic review. Int J Cancer. 2018 Sep 15;143(6):1279-1286. doi: 10.1002/ijc.31337. Epub 2018 Mar 15.

Reference Type: BACKGROUND

PMID: 29468674 (View on PubMed)

Egnell C, Heyman M, Jonsson OG, Raja RA, Niinimaki R, Albertsen BK, Schmiegelow K, Stabell N, Vaitkeviciene G, Lepik K, Harila-Saari A, Ranta S. Obesity as a predictor of treatment-related toxicity in children with acute lymphoblastic leukaemia. Br J Haematol. 2022 Mar;196(5):1239-1247. doi: 10.1111/bjh.17936. Epub 2021 Nov 2.

Reference Type: BACKGROUND

PMID: 34726257 (View on PubMed)

Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, Linda S, Martin PL, Pullen DJ, Viswanatha D, Willman CL, Winick N, Camitta BM; Children's Oncology Group. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood. 2008 Jun 15;111(12):5477-85. doi: 10.1182/blood-2008-01-132837. Epub 2008 Apr 3.

Reference Type: BACKGROUND

PMID: 18388178 (View on PubMed)

Walters M, Mowbray C, Jubelirer T, Jacobs S, Kelly KM, Smith K, Yao Y, Jin Z, Ladas EJ. A bilingual dietary intervention early in treatment is feasible and prevents weight gain in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2021 May;68(5):e28910. doi: 10.1002/pbc.28910. Epub 2021 Feb 15.

Reference Type: BACKGROUND

PMID: 33590674 (View on PubMed)

Limon-Miro AT, Valencia ME, Lopez-Teros V, Aleman-Mateo H, Mendez-Estrada RO, Pacheco-Moreno BI, Astiazaran-Garcia H. An individualized food-based nutrition intervention reduces visceral and total body fat while preserving skeletal muscle mass in breast cancer patients under antineoplastic treatment. Clin Nutr. 2021 Jun;40(6):4394-4403. doi: 10.1016/j.clnu.2021.01.006. Epub 2021 Jan 9.

Reference Type: BACKGROUND

PMID: 33485708 (View on PubMed)

Belanger V, Delorme J, Napartuk M, Bouchard I, Meloche C, Curnier D, Sultan S, Laverdiere C, Sinnett D, Marcil V. Early Nutritional Intervention to Promote Healthy Eating Habits in Pediatric Oncology: A Feasibility Study. Nutrients. 2022 Feb 28;14(5):1024. doi: 10.3390/nu14051024.

Reference Type: BACKGROUND

PMID: 35267999 (View on PubMed)

Orgel E, Framson C, Buxton R, Kim J, Li G, Tucci J, Freyer DR, Sun W, Oberley MJ, Dieli-Conwright C, Mittelman SD. Caloric and nutrient restriction to augment chemotherapy efficacy for acute lymphoblastic leukemia: the IDEAL trial. Blood Adv. 2021 Apr 13;5(7):1853-1861. doi: 10.1182/bloodadvances.2020004018.

Reference Type: BACKGROUND

PMID: 33792627 (View on PubMed)

Braam KI, van der Torre P, Takken T, Veening MA, van Dulmen-den Broeder E, Kaspers GJ. Physical exercise training interventions for children and young adults during and after treatment for childhood cancer. Cochrane Database Syst Rev. 2016 Mar 31;3(3):CD008796. doi: 10.1002/14651858.CD008796.pub3.

Reference Type: BACKGROUND

PMID: 27030386 (View on PubMed)

Revuelta Iniesta R, Gerasimidis K, Paciarotti I, McKenzie JM, Brougham MF, Wilson DC. Micronutrient status influences clinical outcomes of paediatric cancer patients during treatment: A prospective cohort study. Clin Nutr. 2021 May;40(5):2923-2935. doi: 10.1016/j.clnu.2021.03.020. Epub 2021 Mar 20.

Reference Type: BACKGROUND

PMID: 33964502 (View on PubMed)

Glatt D, Hughes C, McCarthy O, O'Shea F, Brougham MFH, Wilson DC, Revuelta Iniesta R. Nutritional screening and assessment of paediatric cancer patients: A quality improvement project (baseline results). Clin Nutr ESPEN. 2020 Aug;38:242-252. doi: 10.1016/j.clnesp.2020.04.003. Epub 2020 Apr 27.

Reference Type: BACKGROUND

PMID: 32690165 (View on PubMed)

Ren Y, Li X. Direct and indirect costs of families with a child with acute lymphoblastic leukaemia in an academic hospital in China: a cross-sectional survey. BMJ Open. 2019 Jul 18;9(7):e030511. doi: 10.1136/bmjopen-2019-030511.

Reference Type: BACKGROUND

PMID: 31324687 (View on PubMed)

Rahiala J, Riikonen P, Kekalainen L, Perkkio M. Cost analysis of the treatment of acute childhood lymphocytic leukaemia according to Nordic protocols. Acta Paediatr. 2000 Apr;89(4):482-7. doi: 10.1080/080352500750028230.

Reference Type: BACKGROUND

PMID: 10830464 (View on PubMed)

Soliman R, Heneghan C, Bolous NS, Sidhom I, Ahmed S, Roberts N, Oke J, Elhaddad A. Systematic review of costs and cost-effectiveness of treatment for relapsed/refractory acute leukemia in children and young adults. Expert Rev Hematol. 2022 Apr;15(4):345-357. doi: 10.1080/17474086.2022.2069096. Epub 2022 May 4.

Reference Type: BACKGROUND

PMID: 35485262 (View on PubMed)

Orgel E, Tucci J, Alhushki W, Malvar J, Sposto R, Fu CH, Freyer DR, Abdel-Azim H, Mittelman SD. Obesity is associated with residual leukemia following induction therapy for childhood B-precursor acute lymphoblastic leukemia. Blood. 2014 Dec 18;124(26):3932-8. doi: 10.1182/blood-2014-08-595389. Epub 2014 Oct 27.

Reference Type: BACKGROUND

PMID: 25349177 (View on PubMed)

Brinksma A, Sanderman R, Roodbol PF, Sulkers E, Burgerhof JG, de Bont ES, Tissing WJ. Malnutrition is associated with worse health-related quality of life in children with cancer. Support Care Cancer. 2015 Oct;23(10):3043-52. doi: 10.1007/s00520-015-2674-0. Epub 2015 Mar 10.

Reference Type: BACKGROUND

PMID: 25752883 (View on PubMed)

Lovell AL, Gardiner B, Henry L, Bate JM, Brougham MFH, Iniesta RR. The evolution of nutritional care in children and young people with acute lymphoblastic leukaemia: a narrative review. J Hum Nutr Diet. 2025 Feb;38(1):e13273. doi: 10.1111/jhn.13273. Epub 2024 Jan 7.

Reference Type: BACKGROUND

PMID: 38185902 (View on PubMed)

Coombs A, Schilperoort H, Sargent B. The effect of exercise and motor interventions on physical activity and motor outcomes during and after medical intervention for children and adolescents with acute lymphoblastic leukemia: A systematic review. Crit Rev Oncol Hematol. 2020 Aug;152:103004. doi: 10.1016/j.critrevonc.2020.103004. Epub 2020 May 27.

Reference Type: BACKGROUND

PMID: 32580035 (View on PubMed)

Oeffinger KC, Mertens AC, Sklar CA, Yasui Y, Fears T, Stovall M, Vik TA, Inskip PD, Robison LL; Childhood Cancer Survivor Study. Obesity in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2003 Apr 1;21(7):1359-65. doi: 10.1200/JCO.2003.06.131.

Reference Type: BACKGROUND

PMID: 12663727 (View on PubMed)

Iniesta RR, Paciarotti I, Brougham MF, McKenzie JM, Wilson DC. Effects of pediatric cancer and its treatment on nutritional status: a systematic review. Nutr Rev. 2015 May;73(5):276-95. doi: 10.1093/nutrit/nuu062. Epub 2015 Mar 29.

Reference Type: BACKGROUND

PMID: 26011902 (View on PubMed)

Revuelta Iniesta R, Paciarotti I, Davidson I, McKenzie JM, Brougham MFH, Wilson DC. Nutritional status of children and adolescents with cancer in Scotland: A prospective cohort study. Clin Nutr ESPEN. 2019 Aug;32:96-106. doi: 10.1016/j.clnesp.2019.04.006. Epub 2019 May 17.

Reference Type: BACKGROUND

PMID: 31221298 (View on PubMed)

Cohen J, Collins L, Gregerson L, Chandra J, Cohn RJ. Nutritional concerns of survivors of childhood cancer: A "First World" perspective. Pediatr Blood Cancer. 2020 Jun;67 Suppl 3:e28193. doi: 10.1002/pbc.28193. Epub 2020 Jan 29.

Reference Type: BACKGROUND

PMID: 31994836 (View on PubMed)

Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet. 2020 Apr 4;395(10230):1146-1162. doi: 10.1016/S0140-6736(19)33018-1.

Reference Type: BACKGROUND

PMID: 32247396 (View on PubMed)

Study Documents

Document Type: Protocol and ethics can be shared on request

Information will be shared following ethical approval on relevant websites

View Document

Other Identifiers

BREVARY_Mad_Exe

Identifier Type: -

Identifier Source: org_study_id